Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962360 | 1.00 | BCHE (0.49) | BCHEBIRC2TAS1R3TAS1R1ACHE | |
| SCHEMBL3957111 | 0.93 | BIRC2 (0.49) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL3956295 | 0.93 | BIRC2 (0.49) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL3957109 | 0.93 | BIRC2 (0.49) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL2503547 | 0.89 | FOLH1 (0.44) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| Hydrochloric Acid SCHEMBL30670634 | 0.87 | TAS1R3 (0.46) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL6821759 | 0.86 | FOLH1 (0.42) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL27589188 | 0.86 | FOLH1 (0.42) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL11932570 | 0.86 | FOLH1 (0.46) | BCHEBIRC2TAS1R3TAS1R1FOLH1 | |
| SCHEMBL6821567 | 0.86 | FOLH1 (0.42) | BCHEBIRC2TAS1R3TAS1R1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8894970-B2 | Arginase inhibitors and methods of use thereof | CORRIDOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8552208-B2 | Analogs of tetramic acid | University of Tennesseee Research Foundation (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2009035553-A2 | ANALOGS OF TETRAMIC ACID | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069406-A1 | Analogs of tetramic acid | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-03-12 | — | — | US | disclosed |
| US-20090069406-A1 | Analogs of tetramic acid | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-03-12 | — | — | US | disclosed |
| CN-1207288-C | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2005-06-22 | — | — | CN | disclosed |
| CN-1208405-A | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 1999-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069406-A1 | Analogs of tetramic acid | TFRC, SLC7A1, FTH1 | BCHE 4379/4885BIRC2 4251/4885TAS1R3 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.